Morgan Stanley Savara Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Savara Inc stock. As of the latest transaction made, Morgan Stanley holds 382,613 shares of SVRA stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

382,613

Previous 255,513 49.74%

Holding current value

$1.56 Million

Previous $707,000 23.34%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.99 - $3.4 $252,929 - $432,140	127,100 Added 49.74%	382,613 $872,000
Q1 2025 May 15, 2025	SELL	$2.32 - $3.14 $325,832 - $440,997	-140,445 Reduced 35.47%	255,513 $707,000
Q4 2024 Feb 14, 2025	SELL	$2.94 - $4.07 $221,667 - $306,865	-75,397 Reduced 16.0%	395,958 $1.22 Million
Q3 2024 May 14, 2025	BUY	$3.96 - $5.07 $847,558 - $1.09 Million	214,030 Added 83.17%	471,355 $2 Million
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $847,558 - $1.09 Million	214,030 Added 83.17%	471,355 $2 Million
Q2 2024 May 14, 2025	SELL	$3.66 - $5.34 $507,396 - $740,300	-138,633 Reduced 35.01%	257,325 $1.04 Million
Q2 2024 Oct 17, 2024	BUY	$3.66 - $5.34 $94,285 - $137,563	25,761 Added 11.12%	257,325 $1.04 Million
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $94,285 - $137,563	25,761 Added 11.12%	257,325 $1.04 Million
Q1 2024 Oct 17, 2024	SELL	$4.19 - $5.59 $107,938 - $144,003	-25,761 Reduced 10.01%	231,564 $1.15 Million
Q1 2024 Aug 16, 2024	BUY	$4.19 - $5.59 $42,126 - $56,201	10,054 Added 4.54%	231,564 $1.15 Million
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $42,126 - $56,201	10,054 Added 4.54%	231,564 $1.15 Million
Q4 2023 Aug 16, 2024	SELL	$3.18 - $4.9 $113,891 - $175,493	-35,815 Reduced 13.92%	221,510 $1.04 Million
Q4 2023 Feb 13, 2024	BUY	$3.18 - $4.9 $462,957 - $713,361	145,584 Added 191.74%	221,510 $1.04 Million
Q3 2023 Nov 15, 2023	SELL	$2.97 - $3.88 $86,943 - $113,583	-29,274 Reduced 27.83%	75,926 $287,000
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $148,256 - $284,232	-87,726 Reduced 45.47%	105,200 $335,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.82 $42,123 - $74,242	-26,327 Reduced 12.01%	192,926 $376,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.64 $31,004 - $45,808	27,932 Added 14.6%	219,253 $339,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $11,108 - $15,355	8,168 Added 4.46%	191,321 $298,000
Q2 2022 Oct 27, 2022	SELL	$1.1 - $1.58 $24,357 - $34,985	-22,143 Reduced 10.79%	183,153 $278,000
Q2 2022 Aug 15, 2022	SELL	$1.1 - $1.58 $24,357 - $34,985	-22,143 Reduced 10.79%	183,153 $278,000
Q1 2022 Oct 27, 2022	BUY	$1.05 - $1.36 $23,250 - $30,114	22,143 Added 12.09%	205,296 $268,000
Q1 2022 May 13, 2022	SELL	$1.05 - $1.36 $120,475 - $156,045	-114,739 Reduced 35.85%	205,296 $268,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $84,887 - $109,374	-81,623 Reduced 20.32%	320,035 $397,000
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $473,956 - $658,719	401,658 New	401,658 $554,000

Others Institutions Holding SVRA

# of Institutions

127

Shares Held

167M

Call Options Held

38.7K

Put Options Held

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $465M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account